Publication:
Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients

Simple item page
dc.contributor.authorSeker, MESUT
dc.contributor.authorISEN, Hayati C.
dc.contributor.authorCevirme, NİDAL
dc.contributor.authorAydin, Sinem
dc.contributor.authorBilici, Ahmet
dc.contributor.authorCOBAN, EZGİ
dc.contributor.authorBulut, HURİ
dc.contributor.authorYASIN, Ayse I.
dc.contributor.authorDemir, TARIK
dc.contributor.authorAliyev, ALTAY
dc.contributor.authorKocyigit, ABDÜRRAHİM
dc.contributor.authorTurk, Haci M.
dc.contributor.institutionauthorŞEKER, MESUT
dc.contributor.institutionauthorÇEVİRME, NİDAL
dc.contributor.institutionauthorBULUT, HURI
dc.contributor.institutionauthorÇOBAN, EZGİ
dc.contributor.institutionauthorDEMİR, TARıK
dc.contributor.institutionauthorALİYEV, ALTAY
dc.contributor.institutionauthorKOÇYİĞİT, ABDÜRRAHİM
dc.contributor.institutionauthorTÜRK, HACI MEHMET
dc.date.accessioned2019-10-05T14:16:20Z
dc.date.available2019-10-05T14:16:20Z
dc.date.issued2018-01-01
dc.description.abstractBackground: The aim of this study was to identify the possible relationship of 5-fluorouracil (5-FU)-related arterial vasoconstriction with urotensin-2 (UT-2), which has a high potential as an endogenic vasoconstrictor. Methods: We assigned the patients to 1 of 3 groups. Patients in group 1 received a bolus of 5-FU, those in group 2 a continuous infusion (CI) of 5-FU, and those in group 3 no 5-FU, which was also a control group. Pre- and post-treatment UT-2 levels and brachial arterial diameters were measured and recorded in all patients. Results: 132 patients were included in the study. Pre-and post-treatment brachial artery diameters were similar in all groups: in group 1 (3.28 +/- 0.52 vs. 3.25 +/- 0.44 mm, p = 0.740), in group 2 (3.57 +/- 0.47 vs. 3.46 +/- 0.45 mm, p = 0.441) and in the control group (3.51 +/- 0.52 vs. 3.25 +/- 0.44 mm, p = 0.818). Pre-and post-treatment UT-2 levels were significantly different in each group: in group 1 (39.5 +/- 30.9 vs. 56.7 +/- 27.1 ng/ml, p = 0.0001), in group 2 (37.7 +/- 33.7 vs. 62.5 +/- 37.7 ng/ml, p = 0.0001) and in the control group (52.9 +/- 40.2 vs. 60.8 +/- 40.7 ng/ml, p = 0.006). Conclusion: Our findings suggest that UT-2 has a high potential as a vasoconstrictor agent in our bodies and its level increases through a bolus or CI 5-FU. Increased UT-2 levels are likely to play a role in 5-FU-related cardiac toxicity pathogenesis. (c) 2018 S. Karger GmbH, Freiburg
dc.identifier
dc.identifier.citationSeker M., ISEN H. C. , Cevirme N., Aydin S., Bilici A., Bulut H., YASIN A. I. , COBAN E., Demir T., Aliyev A., et al., -Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients-, ONCOLOGY RESEARCH AND TREATMENT, cilt.41, ss.545-549, 2018
dc.identifier.urihttps://hdl.handle.net/20.500.12645/3417
dc.language.isoen
dc.titleRole of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients
dc.typeArticle
dspace.entity.typePublication
local.article.journalnamePAMUKKALE TIP DERGİSİ
local.avesis.id5310e2d0-5d27-484f-a9c0-adef038ac2a2
local.avesis.response3287
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
relation.isAuthorOfPublication8a03684e-e421-4a9f-9069-168fc121a5d4
relation.isAuthorOfPublication4ef3c0c8-3c56-4204-b426-7b573bcbfb31
relation.isAuthorOfPublicationc60929f9-74b9-495b-9c3e-282e1a8c4aec
relation.isAuthorOfPublicationb4a79108-dba8-4fd3-a0e2-8ee27b12c3b6
relation.isAuthorOfPublication7024abc2-f738-45d1-8283-a6361cda5c3a
relation.isAuthorOfPublication1a41bbd4-75c4-40d1-81e3-3cadf68518c4
relation.isAuthorOfPublication75babbd2-f46b-4121-aa00-54d883a6f907
relation.isAuthorOfPublication1b3a1540-7e57-405d-8a9d-f926d17dcc29
relation.isAuthorOfPublication.latestForDiscovery1b3a1540-7e57-405d-8a9d-f926d17dcc29
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c
Files
Collections
Silinecekler